| 期 |
栏目 |
标题 |
文件 |
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia |
(Rus)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Treatment of advanced small cell lung cancer. Clinical case and literature review |
(Rus)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review |
(Rus)
|
| 卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis |
(Rus)
|
| 卷 24, 编号 1 (2022) |
CLINICAL ONCOLOGY |
Clinical and morphological features of breast tumors with PIK3CA mutations in Russian patients: Observational study |
(Rus)
(Eng)
|
| 卷 24, 编号 2 (2022) |
CLINICAL ONCOLOGY |
Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study |
(Rus)
|
| 卷 26, 编号 2 (2024) |
Articles |
Quantitative indicators of TREC and KREC excision circles in malignancies: a prospective cohort study |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study |
(Rus)
|
